Exhibit 10.7 GENE LOGIC INC. 1997 NON-EMPLOYEE DIRECTORS' STOCK OPTION PLANGene Logic Inc • October 7th, 1997
RECITALSIndemnity Agreement • October 7th, 1997 • Gene Logic Inc • Delaware
Exhibit 10.31License Agreement • October 7th, 1997 • Gene Logic Inc • Delaware
DRAFT DATED 10/7/97 3,000,000 Shares (1) GENE LOGIC INC. Common Stock UNDERWRITING AGREEMENTGene Logic Inc • October 7th, 1997 • California
Exhibit 10.9 GENE LOGIC INC.Stock Restriction Agreement • October 7th, 1997 • Gene Logic Inc • Delaware
Exhibit 10.13Employment Agreement • October 7th, 1997 • Gene Logic Inc
EMPLOYMENT AGREEMENTEmployment Agreement • October 7th, 1997 • Gene Logic Inc
Exhibit 10.12 EMPLOYMENT AGREEMENTEmployment Agreement • October 7th, 1997 • Gene Logic Inc
Exhibit 10.3 GENE LOGIC INC. 1997 EQUITY INCENTIVE PLANStock Option Agreement • October 7th, 1997 • Gene Logic Inc
TARGET DISCOVERY COLLABORATION AND LICENSE AGREEMENT BETWEEN GENE LOGIC INC. AND PROCTER & GAMBLE PHARMACEUTICALS, INC.Collaboration and License Agreement • October 7th, 1997 • Gene Logic Inc • Delaware
Exhibit 10.29License Agreement • October 7th, 1997 • Gene Logic Inc • Connecticut
LICENSE AGREEMENT AGREEMENT effective on the date of the last signature hereon, by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of...Gene Logic Inc • October 7th, 1997 • Connecticut
Exhibit 10.18 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED,...Gene Logic Inc • October 7th, 1997 • Delaware
trading days prior to the date of exercise, (b) if the Common Stock is then regularly traded over-the-counter, the average of the sale prices or secondarily the closing bid of the Common Stock over the 20 trading day period ending three (3) trading days prior to the date of exercise, or (c) if there is no active public market for the Common Stock, the fair market value thereof shall be determined in good faith by the Company's Board of Directors. In the event the holder of this Warrant exercises this Warrant contingent upon the closing of a public offering, the "fair market value" of a share of Common Stock on the date of exercise shall be equal to the initial price to the public specified in the final prospectus with respect to such public offering. The following diagram illustrates how many shares would then be issued upon exercise pursuant to this Section 1.5: Let FMV = Fair market value per share of Common Stock at date of exercise. PSP = Per share Warrant Price at date of exercise
DRUG TARGET AND DRUG LEAD DISCOVERY COLLABORATION AGREEMENT BETWEEN GENE LOGIC INC. AND JAPAN TOBACCO INC. DATED AS OF SEPTEMBER 9, 1997Target and Drug Lead Discovery Collaboration Agreement • October 7th, 1997 • Gene Logic Inc • Delaware
Exhibit 10.8 GENE LOGIC INC.Stock Restriction Agreement • October 7th, 1997 • Gene Logic Inc • Delaware
WITNESSETHStock Restriction Agreement • October 7th, 1997 • Gene Logic Inc • Delaware
GENE LOGIC INC. AND JAPAN TOBACCO INC. SHARE PURCHASE AGREEMENT SEPTEMBER 9, 1997Share Purchase Agreement • October 7th, 1997 • Gene Logic Inc • Delaware
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80 (b)(4), 200.83 and 230.406 ***Indicates omitted material that is the subject of a confidential treatment request filed separately with the Commission. SOLE COMMERCIAL PATENT LICENSE...Patent License Agreement • October 7th, 1997 • Gene Logic Inc • Tennessee
Exhibit 10.11Rights Agreement • October 7th, 1997 • Gene Logic Inc • Delaware
